Ligand is a high-growth company with economic rights to some of the world's most important medicines.
Ligand’s portfolio covers a diverse array of therapeutic areas, partners and underlying technologies with many products in late stage development.
Ligand’s investment in new technology has resulted in cutting-edge innovations that are making major drugs possible.
Ligand has multiple technologies and unpartnered programs available for out-licensing.
Aug 8, 2022 • 4:01 PM EDT
Ligand Reports Second Quarter 2022 Financial Results
Aug 1, 2022 • 7:22 PM EDT
Ligand Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Jul 22, 2022 • 4:08 PM EDT
Ligand to Report Second Quarter Financial Results on August 8
Aug 8, 2022 • 4:30pm EDT
See all events
Jun 10, 2022 • 8:30am PDT
May 4, 2022 • 4:30pm EDT